HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khalili-Shirazi, A. Articles by Collinge, J. Search for Related Content PubMed PubMed Citation Articles by Khalili-Shirazi, A. Articles by Collinge, J. Pubmed/NCBI databases Substance via MeSH

Protein Conformation Significantly Influences Immune Responses to Prion Protein¹

Azadeh Khalili-Shirazi^*, Sonia Quaratino, Marco Londei, Linda Summers^*, Mourad Tayebi^*, Anthony R. Clarke^*, Simon H. Hawke^*, Graham S. Jackson^* and John Collinge^2,*

^* Medical Research Council Prion Unit, Department of Neurodegenerative Disease, Institute of Neurology, and Institute of Child Health, University College London, London, United Kingdom; and Cancer Research United Kingdom Oncology Unit, Cancer Sciences Division, School of Medicine, University of Southampton, Southampton General Hospital, Southampton, United Kingdom

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
In prion diseases, such as variant Creutzfeldt-Jakob disease normal cellular prion protein (PrP^C), a largely -helical structure is converted to an abnormal conformational isoform (PrP^Sc) that shows an increase in -sheet content. Similarly, the recombinant form of PrP^C (r-PrP) can be converted to a conformation dominated by -sheet (r-PrP) by reduction and mild acidification in vitro, a process that may mimic in vivo conversion following PrP^C internalization during recycling. Despite PrP^Sc accumulation and prion propagation in the lymphoreticular system before detectable neuroinvasion, no Ab response to PrP has been detected, probably due to immune tolerance. To investigate how the immune system may respond to - and -PrP, we immunized Prnp^0/0 mice that are not tolerant of PrP with r-PrP and r-PrP. In this study, we show that although T cells stimulated by these differently folded conformers PrP recognize similar immunodominant epitopes (residues 111–130 and 191–210) the cytokine profile in response to r- and r-PrP was different. Challenge with r-PrP elicited a strong response of IL-5 and IL-10, whereas r-PrP led to an early increased production of IFN-. In addition, immunization with r-PrP led to production of predominantly IgG1 isotype Ab in the sera, whereas after immunization with r-PrP, IgG2b was significantly produced. Thus, both humoral and cellular responses to these differently folded isoforms of the same protein are different, indicating a possible involvement of Th1 and Th2 pathway activation. These differences may be exploitable diagnostically and therapeutically for prion diseases, such as variant Creutzfeldt-Jakob disease.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
The prion diseases or transmissible spongiform encephalopathies are a group of fatal, transmissible, neurodegenerative conditions, which include Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker disease, and kuru in humans, and scrapie and bovine spongiform encephalopathy in animals. The transmissibility of human prion disease has become an intense public health issue because of evidence that bovine spongiform encephalopathy-like prions have infected humans (1, 2, 3). A common feature of all prion diseases is the posttranslational conversion of the normal cellular prion protein (PrP^C),³ a host-encoded GPI-anchored sialoglycoprotein (4), -helical in structure and expressed on most cells including B and T cells (5), into an abnormal isoform termed PrP^Sc (6), structurally dominated by -sheet.

Neither amino acid sequencing nor systematic studies of known covalent posttranslational modifications have shown any consistent differences between PrP^C and PrP^Sc (7). The abnormal isoform, PrP^Sc, is isolated from tissue as a highly aggregated and detergent insoluble polymer, which has markedly increased resistance to proteolysis. PrP^C can be completely digested by the serine protease, proteinase K (PK), while in marked contrast, PK removes between 90 and 100 amino acids from the N terminus of abnormal isoform PrP^Sc, depending upon prion strain type, leaving a large protease-resistant C-terminal fragment (8). At low pH, following reduction of the native disulphide bond, the folded C-terminal domain of human prion protein is shown to exist as a soluble material with -sheet structure (9). It is possible that the in vitro conversion of -PrP to -PrP, caused by reduction and mild acidification (10), might occur in vivo, following PrP^C internalization within the cell during recycling (11), and this could underlie prion propagation (9).

Accumulation of PrP^Sc has been found in the lymphoreticular system in human variant Creutzfeldt-Jakob disease (12, 13). In scrapie-affected mice, prions are associated with splenic B and T cells, but not (14) or very little (15, 16) with circulating PBMCs. In mice, infectious prions are detectable in the spleen and lymph nodes long before they can be detected in the brain (17) (A. Khalili-Shirazi and S. H. Hawke, unpublished observation), and PrP^Sc is accumulated in splenic follicular dendritic cells (FDC) (18, 19, 20). An intact immune system is essential for prion propagation. FDCs are required for neuroinvasion and the development of clinical scrapie, and in turn, B cells are required for maturation of FDCs and formation of germinal centers (21). In addition, PrP^Sc has also been reported to be associated with macrophages and dendritic cells (22, 23, 24, 25, 26).

Despite the involvement of the immune system in PrP^Sc replication and neuroinvasion, no Ab response to PrP has been detected in prion disease. The lack of detectable immunity in prion infection is thought to be largely due to immune tolerance because of the widespread expression of PrP^C in the hemopoietic system (27, 28, 29). Furthermore, attempts to produce PrP^Sc-specific Abs by immunization of Prnp^0/0 mice (that are not tolerant to PrP) with PrP^Sc have been uniformly unsuccessful, although it has recently been reported that Abs raised to the repeat motif of PrP, tyrosine-tyrosine-arginine, can specifically recognize the pathological isoform of the PrP (30). We had previously immunized Prnp^0/0 mice with highly purified human recombinant (r)- and r-PrP (31) to obtain a panel of mAbs that strongly immunoprecipitate native PrP^C and PrP^Sc.⁴ In this study, we have characterized the T cell-mediated immune responses to r- and r-PrP in Prnp^0/0 mice and show that the different conformations of the same protein are able to induce a qualitatively different type of response. Such information may provide insights into both the biology of prion diseases and the potential use of PrP conformers in therapeutic vaccination strategies.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Animals

We used Prnp^0/0 mice (27) backcrossed onto an FVB/N mouse background to study the difference between the immune responses of the two different conformers of r-PrP and r-PrP. These mice were housed under specific pathogen-free conditions. Animal care conformed to national and institutional guidelines.

Ag-r-PrP, -r-PrP, and -PrP peptides

Human and mouse r-PrP^91–231 and r-PrP^91–231 used as Ag were synthesized, as already described (9, 31), r-PrP^91–231 being a soluble -helical monomer and PK-sensitive, whereas r-PrP^91–231 is a soluble monomer, rich in -sheet, and relatively PK-resistant. We used 91–231 rPrP, rather than full-length protein because it more readily forms a stable -form. Also, native PrP^C is completely digested by PK, while depending upon prion strain type, between 90 and 100 amino acids from the N terminus of abnormal isoform PrP^Sc are removed leaving a protease-resistant core (8). Such protease-resistant fractions retain infectivity and transgenic mice expressing N-terminally truncated PrP remain able to support prion propagation (32), arguing that the 91–231 construct is the most appropriate study object.

For epitope mapping we used 20-mer peptides of human PrP sequence 91–231, with 10 residues overlap and 15-mer peptides with 13 residues overlap. Peptides were made by solid phase stepwise synthesis using the Fmoc N-terminal protection strategy, using the Applied Biosystems 433 model automated synthesizer (Advanced Biotechnology Centre, Imperial College London). After synthesis, peptides were cleaved from the solid phase and fully deprotected by standard methods. Purification was performed by reverse phase HPLC. Products were analyzed by reverse phase HPLC and MALDI mass spectrometry.

Immunization

For each arm of the study for T cell experiments, three 4- to 6-wk-old Prnp^0/0 mice (27) backcrossed onto on FVB/N background were used. These mice have been found to respond well to PrP Ag. The mice were immunized s.c./intradermally at the base of the tail, with 100 µg of human r- and r-PrP^91–231 (- and -PrP) in CFA. Animals immunized with PBS in CFA and OVA in CFA were used as negative controls. Inguinal lymph nodes from the immunized mice were excised after 10 days and pooled. From each pool, a single cell suspension was made in RPMI 1640 (Life Technologies, BD Biosciences), supplemented with penicillin (100 IU/ml), streptomycin (100 µg/ml), glutamine (2 mM), 2-ME 0.5 mM, and FCS (10%) to analyze the T cell response in vitro.

For sera Ab production, 6-wk-old Prnp^0/0 mice were immunized s.c. at the base of the tail with 100 µg of either mouse r- or r-PrP^91–231 in CFA, and 3 wk later, boosted s.c. at the base of the tail with 100 µg of r- or r-PrP^91–231 in IFA. The serum from each mouse was tested at day 28, at 1/100 dilution, for responses to r- or r-PrP^91–231 by direct ELISA, coating the plates with rPrP^91–231 at 10 µg/ml in carbonate bicarbonate buffer (pH 8.6). The Ab IgG isotypes were also determined, using a mouse Ig isotyping ELISA kit (BD Biosciences, BD Pharmingen).

For the production of mAbs, Prnp^0/0 mice were immunized s.c. at the base of the tail with 100 µg of Ag (human r- or r-PrP^91–231) in CFA and boosted on days 21 and 42 with 100 µg of the similar Ag in IFA, then finally boosted i.p. on day 50 with 50 µg of the Ag in PBS. Three days after final boosting, single cell suspensions of mouse splenocytes were prepared and fused with the NS0 myeloma cell line, selecting hybridomas using conventional methodology. Detailed methods for screening of these mAbs have been described elsewhere.⁴

Proliferation and cytokine assays

For proliferation assays, T cells derived from the lymph nodes of mice immunized with either r- or r-PrP Ag or control mice were used. The study with r- and r-PrP as Ag were repeated four times and with PBS twice. The T cells were derived from a pool of lymph nodes from three mice and tested in triplicate, presenting the results as stimulation index (SI) ± SE. The cells proliferated to 9000 cpm and a SI of 2.5–4 was considered significant. For proliferation assays, cells were plated in round-bottom 96-well plates (Falcon), at 4 x 10⁵ cells per 0.2-ml well, and for cytokine assays in 24-well plates, at 1–2 x 10⁶ cells per 2-ml well. Human r- and r-PrP were sterile filtered through a 0.2-µm filter (Nalgene), titrated in culture for T cell proliferation, and 50 µg/ml was found to be the optimal concentration. Human PrP peptides were also sterile filtered and used at 10 µg/ml. Where appropriate, OVA at 50 µg/ml was used as negative control Ag. Cells were maintained in a standard 72-h proliferation assay and pulsed with [³H]thymidine (0.5 µCi/well) (Amersham Biosciences) in the last 18 h prior to harvesting (TomTec cell harvester) and determining cpm, using a beta counter (Microbeta counter; PerkinElmer).

The production of cytokines from cells in lymph nodes were measured in vitro after 24, 48, and 72 h. IL-2, IL-4, IL-5, IL-10, TGF-, and IFN- were analyzed by sandwich ELISA, using standard protocols, including a standard curve for each plate (BD Biosciences, BD Pharmingen).

Characterization of anti-PrP mAbs

As previously described, mAbs ICSM4, -10, and -18 were obtained upon immunization with r-PrP^91–231 while ICSM35 and -37 with r-PrP^91–231.⁴ ICSM18 and -35 were tested for staining native PrP, in a Rocky Mountain Laboratory isolate of Chandler mouse scrapie prion (RML) (33) -infected neuroblastoma cell line (N2a) (33, 34). The cells were grown in culture on multichamber slides (Sigma-Aldrich) until semiconfluent. To label cell surface PrP, they were incubated at 4°C with anti-PrP mAbs, before fixation with paraformaldehyde. For detection, FITC-conjugated anti-mouse secondary Ab was used.

ELISA

Direct ELISA method was used to detect binding of ICSM18 and -35 to r- and r-PrP^91–231 at 20–10 µg/ml, using anti-mouse IgG (Fab-specific) HRP (Sigma-Aldrich) as secondary Ab and o-phenylenediamine (Sigma-Aldrich) as chromogen. Direct ELISA for detection of native PrP proved difficult, despite using different brain homogenate concentrations, plate manufactures, coating-buffers (carbonate bicarbonate (pH 9.5), Tris (pH 8.5), and PBS (pH 7.4)), blocking solutions (normal goat serum, normal mouse serum, FCS, BSA, and soya milk), and temperatures (4°, 23°, and 37°C), so an indirect sandwich ELISA technique was devised. ICSM18 and ICSM35 were individually used to coat the ELISA plate and after washing, normal or scrapie-affected brain homogenate was added as Ag, and PrP was detected with biotinylated (B) mAb ICSM18B or ICSM35B, using a different mAbs for capture and detection. Finally streptavidin-HRP was added and o-phenylenediamine was used as chromogen. The brain homogenates were tested at 0.5–0.1%, the mAb used for PrP capture coating the ELISA plate was tested at IgG concentrations of 2–10 µg/ml, and the biotinylated mAb used for PrP detection was tested at IgG concentrations of 1 and 0.5 µg/ml. Both ICSM18 and 35 worked well for capturing and for detecting native PrP.

The isotypes of these mAbs were determined using a panel of anti-mouse Ig subclass-specific mAbs (Pierce) and their immunodominant epitopes were defined by direct ELISA, using 20-mer synthetic peptides (10–20 µg/ml), spanning the PrP sequence 91–231 overlapping by 10 residues. These epitopes were further refined by direct peptide ELISA, using 15-mer peptides overlapping by 13 residues. The accuracy of the immunodominant epitopes found was reconfirmed by competition and inhibition ELISA, where the peptides were used to inhibit binding to recombinant r- and r-PrP. For these studies, ELISA plates were coated with r- and r-PrP and the mAbs were tested either by preincubating them with the peptides to inhibit binding to r- and r-PrP, or the peptides were added simultaneously as the mAb to ELISA plates, to compete for the binding of the mAbs to r- and r-PrP. Similar results were obtained, and the latter method was mainly conducted. ELISA plates were coated with r- or r-PrP (20–10 µg/ml) in carbonate/bicarbonate buffer (pH 9.5), to which each mAb IgG (1 µg/ml) and peptide (10–50 µg/ml) were added. The ELISA was then conducted by conventional methods as described above.

Statistical analysis

Data were analyzed for statistical significance using ANOVA and two-tailed t test.

	Results

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
Both r- and r-PrP are recognized by T cells

Immunization with either r- or r-PrP evoked clear proliferative T cell responses to both r- or r-PrP Ags (Fig. 1), unlike T cells from immunizations with PBS-CFA (Fig. 1) or OVA-CFA (data not shown). There was no significant difference between the in vitro recognition of r- and -PrP by T cells derived from either r- or r-PrP immunization (p = 0.316, p = 0.154, two-tailed t test). The viability and Ag-recognition pathway of all the T cells was tested by their response to stimulation with anti-CD3 Ab, where a mean SI of 7–12 was observed (data not shown).

View larger version (8K): [in this window] [in a new window]   FIGURE 1. In vitro T cell proliferation, by -PrP and -PrP challenge. The mean SI ± SEM of lymph nodes T cells from animals immunized with -PrP, -PrP, and PBS is shown, after in vitro challenge with -PrP () and -PrP (). The data of - and -PrP are the means of four experiments (and those for PBS from two), each done in triplicate, using T cells derived from a pool of lymph nodes of three mice. The mean ± SEM of the absolute cpm of unstimulated control cultures from -PrP immunization = 1535 ± 346, -PrP immunization = 1419 ± 325, and from PBS immunization = 1093 ± 378.

T cell epitope recognition of r- and r-PrP is similar

T cells from r- and r-PrP immunizations showed no significant difference in their recognition of PrP peptides (Fig. 2, A and B). T cells from lymph nodes of both r-PrP (Fig. 2A) and r-PrP (Fig. 2B) immunized mice recognized N-terminal residues within the sequence 111–130 and C-terminal residues within 191–210 (p = 0.005, ANOVA). In keeping with the previous result, T cells from PBS (or OVA)-immunized mice did not proliferate in response to PrP peptides (Fig. 2C and data not shown). PrP residues 111–130 are thought to be within the structured part of PrP while residues 191–220 are just C-terminal to the glycosylation sites of PrP.

View larger version (18K): [in this window] [in a new window]   FIGURE 2. Immunodominant epitope of -PrP and -PrP immunized T cells. The mean SI ± SEM of lymph nodes T cells, four experiments with three animals, immunized with A, r-PrP (); B, r-PrP (); and C, PBS () (one experiment), challenged in vitro with 20-mer synthetic peptides spanning PrP 91–231 overlapping by 10 residues. Each experimental mean is that of triplicate readings. The mean ± SEM of the absolute cpm of unstimulated control cultures from -PrP immunization = 1535 ± 346, -PrP immunization = 1419 ± 325, and from PBS immunization = 1093 ± 378.

The cytokines produced by r- and r-PrP-derived T cells are different

The overall proliferation of T cells from Prnp^0/0 mice, and in particular proliferation to PrP peptides was weak. Therefore, we checked for differences in cytokine profiles of lymph node cells from r- and r-PrP immunized mice. Measuring cytokines, in cultures of lymph nodes cells challenged in vitro with rPrP, was most suitable after 24 h and 48 h. Although there was some overlap of the cytokines produced, T cells from lymph nodes of r-PrP-immunized mice were skewed more toward Th1 (producing more IFN- and sooner, and less IL-5 and IL-10), whereas those from r-PrP immunization were skewed more toward Th2 (producing more IL-5 and IL-10, and less or later IFN-) (Fig. 3).

View larger version (11K): [in this window] [in a new window]   FIGURE 3. In vitro Th1 and Th2 cytokine production of -PrP- and -PrP-derived T cells. Lymph nodes T cells from animals immunized with -PrP, -PrP, and PBS were challenged in vitro with -PrP (), -PrP (), and PBS (), and their cytokine production was measured. Unless stated otherwise, data are for 48-h sampling time for IFN- (A), IL-5 (B), IL-10 (C), and IL-2 (D), by T cells derived from pools of lymph nodes of three mice immunized with -PrP, -PrP, and PBS, measured by ELISA. IFN- production for the in vitro stimulation of -PrP immunized T cells with -PrP was not tested, because enough cells were not available. Where there are interrupted bars in the figure, the amount of cytokines produced was off scale.

Th2-induced cytokines like IL-5 and IL-10 were also investigated. IL-5 production was substantially higher after in vitro stimulation with r-PrP compared with r-PrP, by T cells from both r-PrP (p = 0.001, t test) and r-PrP (p = 0.0108, t test) immunizations. T cells from r-PrP-immunized mice produced 227 pg/ml IL-5 in response to r-PrP but only 90 pg/ml in response to r-PrP, and T cells from r-PrP-immunized mice produced 122 pg/ml in response to r-PrP and only 16 pg/ml in response to r-PrP (Fig. 3B). The T cells from r-PrP-immunized mice also produced significantly more IL-5 in response to in vitro stimulation with r-PrP, than those from r-PrP immunization (p = 0.0147, t test). No IL-5 was produced by T cells from PBS-immunized mice, regardless of using r- or r-PrP for the in vitro challenges (Fig. 3B). The IL-10 responses showed that it was produced, slightly more by T cells from r-PrP than r-PrP-immunized mice (Fig. 3C).

Not surprisingly, in view of the results shown in Figs. 1 and 2, there was no statistical difference in the production of IL-2 in response to either r- or r-PrP from both control groups (Fig. 3D), and small amounts of IL-2 was also produced by T cells from PBS-immunized mice, after in vitro challenge with r- or r-PrP (Fig. 3D). Production of IL-4 and TGF- are not shown, as they could not be convincingly measured.

PrP conformation influences the Ab Ig isotypes produced in the sera

Total IgG Ab levels were similar in mice immunized with r- and r-PrP and their sera Abs were positive to r- and r-PrP Ags by ELISA, while no Ab to r- and r-PrP was present in the serum of the unimmunized mouse (Fig. 4A). However, a significant difference was observed in the Ig isotypes produced in the sera of mice immunized with r-PrP, as compared with those immunized with r-PrP. Immunization with r-PrP evoked predominantly Th2 isotype Abs of IgG1 isotype, whereas r-PrP evoked mainly Th1 IgG2b in the serum (Fig. 4B).

View larger version (15K): [in this window] [in a new window]   FIGURE 4. A, Serum Abs are produced in mice immunized with -PrP and -PrP. Sera from Prnp0/0 mice immunized with r-PrP (), r-PrP (), or not immunized () were tested at 1/100 dilution against r-PrP or r-PrP (20 µg/ml) by ELISA. Anti-mouse Ig (Fab -specific)-HRP (Sigma-Aldrich) was used as secondary Ab. B, Different serum Ab Ig isotypes are produced after immunization with -PrP and -PrP. The ELISA results of the total Ig isotypes, as the mean OD ± SEM, are shown for sera of mice immunized with r-PrP (), r-PrP (), and not immunized (). The sera from three mice immunized with r-PrP, three mice immunized with -PrP, and three unimmunized mice were tested in duplicate at 1/100 dilution. C, Different serum anti-PrP Ab Ig isotypes are produced after immunization with -PrP and -PrP. Sera from three mice immunized with r-PrP () and three mice immunized with -PrP () were tested in duplicates at 1/100 dilution in a r-PrP ELISA, using different anti-mouse IgG isotype-specific HRP and IgM HRP (DakoCytomation) secondary Abs. The r-PrP ELISA data are shown as mean OD ± SEM.

PrP conformation affects the IgG isotype and the specificity of the mAbs produced

A significant difference was also observed in the specificity and IgG isotype of the mAbs raised against - and -isoforms of PrP. The results obtained for the mAbs produced to r- and r-PrP further demonstrate that PrP in the different conformations ( or ) give rise to a different type of cellular response, skewed more toward Th1 for r-PrP and Th2 for r-PrP. This reconfirms the data already obtained for T cells and the sera Ab Ig isotypes. ICSM4, -10, -18, -35, and -37 mAbs, raised to r- and -PrP, had different specificities and IgG isotypes. Those produced against r-PrP (ICSM4, -10, and -18) were of IgG1 isotype, whereas r-PrP-derived mAbs (ICSM35 and -37) were IgG2b and IgG2a.⁴ Furthermore, IgG isotypes were also different in the 40 mAbs we have produced to r-PrP and 41 mAbs to r-PrP. The isotypes of the mAbs produced from r-PrP immunizations were 92.5% IgG1 and 7.5% IgG2 (2.5% IgG2a and 5% IgG2b), whereas the isotypes of those produced to r-PrP immunizations were 53.6% IgG1, 41.5% IgG2 (12.2% IgG2a, 29.3% IgG2b), and 4.9% IgM (manuscript in preparation).

Both ICSM18 and ICSM35 (raised against r- and r-PrP respectively), were equally suitable for capturing or detecting native PrP from normal and RML-infected scrapie-affected mouse brain homogenates by sandwich ELISA (Fig. 5A). As previously described ICSM4, -10, and -18 (raised to r-PrP) and ICSM35 and 37 (raised to r-PrP) were all positive to denatured PrP^C and PK-treated PrP^Sc in a Western blot, but they recognized different PrP glycoforms.⁴ The Western blots of ICSM18 and ICSM35 showed that they both recognize all the PrP glycoforms (Fig. 5B). In contrast, ICSM4 only recognized unglycosylated PrP^C and PrP^Sc, while ICSM18 recognized di-, mono-, and unglycosylated PrP^C and PrP^Sc, by Western blot using aliquots of the same normal and scrapie-affected mouse brain homogenates (Fig. 5B). ICSM4 and -10 also differentially immunoprecipitated PrP glycoforms from PrP^C, while anti--PrP mAbs ICSM35 and -37 did not.⁴ ICSM18 and ICSM35 were chosen, as strongly binding representatives of PrP-specific Th2 response for -PrP and Th1 response for -PrP.

View larger version (27K): [in this window] [in a new window]   FIGURE 5. Detection of PrP by ELISA (A) and Western blotting (B), using -PrP- and -PrP-derived mAbs. A, ICSM18 and -35 were tested for their ability to capture (at IgG 10 µg/ml) and detect (at IgG 0.5 µg/ml) PrP in an indirect sandwich ELISA, using normal wild-type (Wt) mouse brain homogenate, RML-infected scrapie-affected (Sc) brain homogenate and PBS as Ag. For the ELISA, either ICSM18 was used for PrP capture and ICSM35B for detection () or ICSM35 was used for PrP capture and ICSM18B for detection (). B, ICSM18 and ICSM35 recognize all three PrP bands by Western blot, representing unglycosylated (29 kDa), monoglycosylated (33 kDa), and diglycosylated PrP (36 kDa), in murine PrPC and PrPSc. ICSM4 labeled the full-length unglycosylated PrP band (29 kDa), but not the mono- and diglycosylated bands in normal (N) brain homogenate. After PK treatment (+PK), all the truncated and the PrPC bands were digested from scrapie-affected (Scrapie) brain homogenate and only PrPSc bands were recognized at reduced molecular weights of diglycosylated (33 kDa), monoglycosylated (28 kDa), and unglycosylated (20 kDa) PrP. No binding to PrP was observed, when isotype control-negative mAbs were used and the above mAbs were negative, when tested against Prnp0/0 mouse brain (data not shown).

View larger version (78K): [in this window] [in a new window]   FIGURE 6. Immunofluoresence labeling of native PrP on RML-infected N2a cells by anti-- and -PrP mAbs. ICSM18 (A) and ICSM35 (B) successfully labeled PrP on RML-infected N2a cells. The cells were grown on multichamber glass slides, and when semiconfluent, they were directly incubated with the mAbs. An irrelevant mAb (C) and no primary Ab, second layer alone (D) were used as negative control.

View larger version (30K): [in this window] [in a new window]   FIGURE 7. Immunodominant epitope of anti--PrP and -PrP mAbs determined by ELISA. The mAbs were epitope mapped by ELISA, using 15-mer peptides spanning the relevant PrP sequence, overlapping by 13 residues. Data are shown for (A) anti--PrP mAb ICSM 18 (), and isotype control (); and (B) anti--PrP mAbs ICSM 35 () and 37 (), using ICSM18 () as negative control for these peptide sequences. Their epitopes had originally been located with the 20-mer peptides used in Fig. 2. The finer specificities are further confirmed by competition with the peptides, in inhibiting the binding of (C) ICSM18 and (D) ICSM35 to -PrP () or -PrP (). The mAbs were added together with the competitor peptides.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
In this study, we have demonstrated that immunization of mice with either - or -PrP evokes a different cytokine milieu and Ab isotype profile. Usually CD4⁺ T cells recognize linear processed peptides presented in the groove of MHC class II molecules, whereas B cells recognize both conformational and/or linear epitopes of an Ag. When we immunized PrP-deficient mice (of FVB/N MHC H-2^q haplotype) with either r- or r-PrP, comparable T cell proliferation against similar immunodominant epitopes was observed. Although - and -PrP do not differ in amino acid sequence, they elicited qualitatively different cellular and humoral response. Although T cells from r- and r-PrP immunizations recognized both r- and r-PrP and peptide residues 111–130 and 191–210; by contrast the mAbs reflecting the activity of B cells could partially discriminate between PrP^C and PrP^Sc, and their immunodominant peptides were different: 93–105 for r-PrP immunizations (ICSM35 and -37) and 143–153 for r-PrP (ICSM18).

We have observed that the T cell proliferation, particularly against PrP peptides, was weak. One possible explanation for this could be the absence of PrP in the cells of Prnp^0/0 mice. Lack of PrP^C on T lymphocytes could lead to generally low activation levels, as we found that even the response to soluble anti-CD3 Ab was very modest. Indeed, PrP^C may have an important role in T cell activation. PrP^C is significantly up-regulated on mouse T cells upon challenge with concanavalin A (Con-A), but in Prnp^0/0 mice, T cell response to Con-A is significantly reduced to 50–80%, suggesting that PrP^C is a lymphocyte surface molecule that participates in T cell activation (35). In human T lymphocytes, PrP^C expression is also increased upon challenge with Con-A and reduced by the addition of anti-PrP polyclonal Ab (36). PrP^C expression on normal human T lymphocytes is also increased after challenge with either Con-A or anti-CD3 Ab and inhibited by addition of anti-PrP mAbs, and in addition, CD45RO⁺ memory T cells consistently expressed more PrP^C than CD45RA⁺ naive T lymphocytes (37). A recent report suggests PrP^C to be a component of the multimolecular signaling complex, within microdomains involved in T cell activation (38). The absence of PrP^C on T lymphocytes of Prnp^0/0 mice may therefore be responsible for the weak proliferative response we have observed in this study, but apparently it does not affect their cytokine production. The proliferation response was particularly weak after in vitro challenge with the peptides, but in a preliminary study we have found that splenocyte T cells from r-PrP-immunized mice produce IL-5 in response to in vitro challenge with peptide sequence 191–210, and T cells from both r- and r-PrP immunizations produce IFN- in response to this peptide (S. H. Hawke and Z. Sattar, unpublished data). Sera Abs were also positive to this epitope after immunization of Prnp^0/0 mice with rPrP (A. Khalili-Shirazi and L. Summers, unpublished observation).

The processing of different proteins by different APCs, such as dendritic cells and macrophages, leads to activation of different signaling pathways leading to the production of different cytokines (39). T cell activation leads to a CD4⁺ or CD8⁺ T cell response, CD4⁺ initiating either a Th1 or Th2 immunity, each triggering production of a series of different cytokines and IgG isotypes (40, 41, 42). Th1 type response leads to activation of macrophages and is characterized by production of IFN-, whereas Th2 leads to activation of different APCs, and production of IL-4, IL-5, and IL-10 (43, 44). This dichotomy might be interpreted as the result of different T cell activation. Indeed, it has been reported that Th2 cells provide B cell help and stimulate the production of noncomplement fixing IgG1 Abs, while Th1 cells induce B cells to switch to IgG2 and IgG3 (45).

In this study, we have shown that despite some overlap, the immune response to r-PrP was skewed more toward Th2, inducing T cells to produce increased amounts of IL-5 and IL-10, and B cells to produce polyclonal IgG1 Abs in the sera, and IgG1 mAbs such as ICSM4, -10, and -18. In contrast, the immune response to r-PrP was skewed more toward Th1, with a high and early production of IFN-, less IL-5 and IL-10 cytokines, and production of serum IgG2b isotype Abs and IgG2b and IgG2a mAbs, like ICSM35 and -37. These data indicate that different APCs may be involved in processing of r- and r-PrP. When r-PrP is used as the immunogen, its greater sensitivity to proteolytic cleavage might mean that it is more easily processed for presentation to B cells and may involve different APCs from those that process r-PrP. In comparison with r-PrP, r-PrP is rich in -sheet and partially PK-resistant (9). It is possible that r-PrP is mainly processed by B cells and dendritic cells and much less by macrophages, whereas -PrP is mainly processed by macrophages and less by B cells or dendritic cells. Immune tolerance to PrP in Prnp^+/+ mice can reportedly be overcome by improved immunization techniques, using mouse rPrP (46) and dimeric mouse rPrP (47), leading to production of anti-PrP polyclonal Abs. In the course of prion inoculation, activated T cells have been detected in the brain and spleen of mice affected with scrapie (48). Macrophages appear to have an important role in neutralizing infectivity (23) and an association between dendritic cells and PrP^Sc has been reported (26, 49). Our findings may provide an insight into how PrP^C and PrP^Sc might be differentially processed by APCs, such as dendritic cells and macrophages. The data presented in this study on the immune responses to r- and r-PrP might reflect those to PrP^C and PrP^Sc, if there was no tolerance to PrP or if it could be overcome by vaccination. A transient, but undetected, immune response may also occur early in the course of prion infection, when conversion of PrP^C to PrP^Sc has just begun and before formation of large PrP^Sc deposits and onset of clinical signs. These findings may therefore be relevant to the understanding of the molecular mechanisms underlying prion diseases in humans and help in the design of an effective therapeutic immunization or vaccination approach.

	Disclosures

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 
J. Collinge and G. S. Jackson are consultants and shareholders in D-Gen Ltd., and J. Collinge is also a Director.

	Acknowledgments

 
We thank Daljit Bhelt for technical help in making the rPrP, the Central Biomedical Services staff of Imperial College London at Charing Cross campus, and Ray Young for graphics.

	Footnotes

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was funded by the United Kingdom Medical Research Council.

² Address correspondence and reprint requests to Dr. John Collinge, Medical Research Council Prion Unit, Department of Neurodegenerative Disease, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, U.K. E-mail address: j.collinge{at}prion.ucl.ac.uk

³ Abbreviations used in this paper: PrP^C, cellular prion protein; PrP^Sc, abnormal isoform prion protein; PK, proteinase K; FDC, follicular dendritic cells; r, recombinant; RML, Rocky Mountain Laboratory isolate of Chandler mouse scrapie prion; SI, stimulation index; B, biotinylated; Con-A, concanavalin A.

⁴ A. Khalili-Shirazi, L. Summers, J. Linehan, G. Mallinson, D. Anstee, S. Hawke, G. S. Jackson, and J. Collinge. PrP glycoforms are associated in a strain-specific ratio in native PrP^Sc. Submitted for publication.

Received for publication April 5, 2004. Accepted for publication January 4, 2005.

	References

Top Abstract Introduction Materials and Methods Results Discussion Disclosures References

 

1. Collinge, J., K. C. L. Sidle, J. Meads, J. Ironside, A. F. Hill. 1996. Molecular analysis of prion strain variation and the aetiology of "new variant" CJD. Nature 383:685.[Medline]
2. Hill, A. F., M. Desbruslais, S. Joiner, K. C. L. Sidle, I. Gowland, J. Collinge. 1997. The same prion strain causes vCJD and BSE. Nature 389:448.[Medline]
3. Bruce, M. E., R. G. Will, J. W. Ironside, I. McConnell, D. Drummond, A. Suttie, L. McCardle, A. Chree, J. Hope, C. Birkett, et al 1997. Transmissions to mice indicate that "new variant" CJD is caused by the BSE agent. Nature 389:498.[Medline]
4. Stahl, N., D. R. Borchelt, K. Hsiao, S. B. Prusiner. 1987. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 51:229.[Medline]
5. Presky, D. H., M. G. Low, E. M. Shevach. 1990. Role of phosphatidylinositol-anchored proteins in T cell activation. J. Immunol. 144:860.[Abstract]
6. Prusiner, S. B.. 1991. Molecular biology of prion diseases. Science 252:1515.[Abstract/Free Full Text]
7. Stahl, N., M. A. Baldwin, D. B. Teplow, L. Hood, B. W. Gibson, A. L. Burlingame, S. B. Prusiner. 1993. Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing. Biochemistry 32:1991.[Medline]
8. Prusiner, S. B.. 1982. Novel proteinaceous infectious particles cause scrapie. Science 216:136.[Abstract/Free Full Text]
9. Jackson, G. S., L. L. P. Hosszu, A. Power, A. F. Hill, J. Kenney, H. Saibil, C. J. Craven, J. P. Waltho, A. R. Clarke, J. Collinge. 1999. Reversible conversion of monomeric human prion protein between native and fibrilogenic conformations. Science 283:1935.[Abstract/Free Full Text]
10. Hosszu, L. L. P., N. J. Baxter, G. S. Jackson, A. Power, A. R. Clarke, J. P. Waltho, C. J. Craven, J. Collinge. 1999. Structural mobility of the human prion protein probed by backbone hydrogen exchange. Nat. Struct. Biol. 6:740.[Medline]
11. Shyng, S.-L., M. T. Huber, D. A. Harris. 1993. A prion protein cycles between the cell surface and an endocytic compartment in cultured neuroblastoma cells. J. Biol. Chem. 268:15922.[Abstract/Free Full Text]
12. Wadsworth, J. D. F., S. Joiner, A. F. Hill, T. A. Campbell, M. Desbruslais, P. J. Luthert, J. Collinge. 2001. Tissue distribution of protease resistant prion protein in variant CJD using a highly sensitive immuno-blotting assay. Lancet 358:171.[Medline]
13. Hill, A. F., R. J. Butterworth, S. Joiner, G. Jackson, M. N. Rossor, D. J. Thomas, A. Frosh, N. Tolley, J. E. Bell, M. Spencer, et al 1999. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 353:183.[Medline]
14. Raeber, A. J., M. A. Klein, R. Frigg, E. Flechsig, A. Aguzzi, C. Weissmann. 1999. PrP-dependent association of prions with splenic but not circulating lymphocytes of scrapie-infected mice. EMBO J. 18:2702.[Medline]
15. Brown, P., L. Cervenáková, L. M. McShane, P. Barber, R. Rubenstein, W. N. Drohan. 1999. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 39:1169.[Medline]
16. Cervenakova, L.. 2001. The safety of human blood: experimental TSE/prion infectivity studies. Transfus. Clin. Biol. 8:260.[Medline]
17. Blättler, T., S. Brandner, A. J. Raeber, M. A. Klein, T. Voigtländer, C. Weissmann, A. Aguzzi. 1997. PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature 389:69.[Medline]
18. Brown, K. L., K. Stewart, D. L. Ritchie, N. A. Mabbott, A. Williams, H. Fraser, W. I. Morrison, M. E. Bruce. 1999. Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells. Nat. Med. 5:1308.[Medline]
19. Montrasio, F., R. Frigg, M. Glatzel, M. A. Klein, F. Mackay, A. Aguzzi, C. Weissmann. 2000. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science 288:1257.[Abstract/Free Full Text]
20. Mabbott, N. A., F. Mackay, F. Minns, M. E. Bruce. 2000. Temporary inactivation of follicular dendritic cells delays neuroinvasion of scrapie. Nat. Med. 6:719.[Medline]
21. Klein, M. A., R. Frigg, E. Flechsig, A. J. Raeber, U. Kalinke, H. Bluethmann, F. Bootz, M. Suter, R. M. Zinkernagel, A. Aguzzi. 1997. A crucial role for B cells in neuroinvasive scrapie. Nature 390:687.[Medline]
22. Prinz, M., F. Montrasio, M. A. Klein, P. Schwarz, J. Priller, B. Odermatt, K. Pfeffer, A. Aguzzi. 2002. Lymph nodal prion replication and neuroinvasion in mice devoid of follicular dendritic cells. Proc. Natl. Acad. Sci. USA 99:919.[Abstract/Free Full Text]
23. Beringue, V., M. Demoy, C. I. Lasmézas, B. Gouritin, C. Weingarten, J. P. Deslys, J. P. Andreux, P. Couvreur, D. Dormont. 2000. Role of spleen macrophages in the clearance of scrapie agent early in pathogenesis. J. Pathol. 190:495.[Medline]
24. Shlomchik, M. J., K. Radebold, N. Duclos, L. Manuelidis. 2001. Neuroinvasion by a Creutzfeldt-Jakob disease agent in the absence of B cells and follicular dendritic cells. Proc. Natl. Acad. Sci. USA 98:9289.[Abstract/Free Full Text]
25. Burthem, J., B. Urban, A. Pain, D. J. Roberts. 2001. The normal cellular prion protein is strongly expressed by myeloid dendritic cells. Blood 98:3733.[Abstract/Free Full Text]
26. Luhr, K. M., R. P. Wallin, H. G. Ljunggren, P. Low, A. Taraboulos, K. Kristensson. 2002. Processing and degradation of exogenous prion protein by CD11c⁺ myeloid dendritic cells in vitro. J. Virol. 76:12259.[Abstract/Free Full Text]
27. Bueler, H., A. Aguzzi, A. Sailer, R. A. Greiner, P. Autenried, M. Aguet, C. Weissmann. 1993. Mice devoid of PrP are resistant to scrapie. Cell 73:1339.[Medline]
28. Kingsbury, D. T., D. A. Smeltzer, C. J. Gibbs, Jr, D. C. Gajdusek. 1981. Evidence for normal cell-mediated immunity in scrapie-infected mice. Infect. Immun. 32:1176.[Abstract/Free Full Text]
29. Porter, D. D., H. G. Porter, N. A. Cox. 1973. Failure to demonstrate a humoral immune response to scrapie infection in mice. J. Immunol. 111:1407.[Abstract/Free Full Text]
30. Paramithiotis, E., M. Pinard, T. Lawton, S. LaBoissiere, V. L. Leathers, W. Q. Zou, L. A. Estey, J. Lamontagne, M. T. Lehto, L. H. Kondejewski, et al 2003. A prion protein epitope selective for the pathologically misfolded conformation. Nat. Med. 9:893.[Medline]
31. Jackson, G. S., A. F. Hill, C. Joseph, L. L. P. Hosszu, A. R. Clarke, J. Collinge. 1999. Multiple folding pathways for heterologously expressed human prion protein. Biochim. Biophys. Acta 1431:1.[Medline]
32. Flechsig, E., D. Shmerling, I. Hegyi, A. J. Raeber, M. Fischer, A. Cozzio, C. von Mering, A. Aguzzi, C. Weissmann. 2000. Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice. Neuron 27:399.[Medline]
33. Chandler, R. L.. 1961. Encephalopathy in mice produced by inoculation with scrapie brain material. Lancet 277:1378.
34. Enari, M., E. Flechsig, C. Weissmann. 2001. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl. Acad. Sci. USA 98:9295.[Abstract/Free Full Text]
35. Mabbott, N. A., K. L. Brown, J. Manson, M. E. Bruce. 1997. T-lymphocyte activation and the cellular form of the prion protein. Immunology 92:161.[Medline]
36. Cashman, N. R., R. Loertscher, J. Nalbantoglu, I. Shaw, R. J. Kascsak, D. C. Bolton, P. E. Bendheim. 1990. Cellular isoform of the scrapie agent protein participates in lymphocyte activation. Cell 61:185.[Medline]
37. Li, R., D. Liu, G. Zanusso, T. Liu, J. D. Fayen, J. H. Huang, R. B. Petersen, P. Gambetti, M. S. Sy. 2001. The expression and potential function of cellular prion protein in human lymphocytes. Cell. Immunol. 207:49.[Medline]
38. Mattei, V., T. Garofalo, R. Misasi, A. Circella, V. Manganelli, G. Lucania, A. Pavan, M. Sorice. 2004. Prion protein is a component of the multimolecular signaling complex involved in T cell activation. FEBS Lett. 560:14.[Medline]
39. Steinman, R. M.. 2003. Some interfaces of dendritic cell biology. APMIS 111:675.[Medline]
40. Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin, R. L. Coffman. 1986. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136:2348.[Abstract]
41. Mosmann, T. R., R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145.[Medline]
42. Lederer, J. A., V. L. Perez, L. DesRoches, S. M. Kim, A. K. Abbas, A. H. Lichtman. 1996. Cytokine transcriptional events during helper T cell subset differentiation. J. Exp. Med. 184:397.[Abstract/Free Full Text]
43. Fiorentino, D. F., M. W. Bond, T. R. Mosmann. 1989. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170:2081.[Abstract/Free Full Text]
44. Kelso, A.. 1995. Th1 and Th2 subsets: paradigms lost?. Immunol. Today 16:374.[Medline]
45. Snapper, C. M., W. E. Paul. 1987. Interferon- and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236:944.[Abstract/Free Full Text]
46. Sigurdsson, E. M., D. R. Brown, M. Daniels, R. J. Kascsak, R. Kascsak, R. Carp, H. C. Meeker, B. Frangione, T. Wisniewski. 2002. Immunization delays the onset of prion disease in mice. Am. J. Pathol. 161:13.[Abstract/Free Full Text]
47. Gilch, S., F. Wopfner, I. Renner-Muller, E. Kremmer, C. Bauer, E. Wolf, G. Brem, M. H. Groschup, H. M. Schatzl. 2003. Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J. Biol. Chem. 278:18524.[Abstract/Free Full Text]
48. Lewicki, H., A. Tishon, D. Homann, H. Mazarguil, F. Laval, V. C. Asensio, I. L. Campbell, S. DeArmond, B. Coon, C. Teng, et al 2003. T cells infiltrate the brain in murine and human transmissible spongiform encephalopathies. J. Virol. 77:3799.[Abstract/Free Full Text]
49. Huang, F. P., C. F. Farquhar, N. A. Mabbott, M. E. Bruce, G. G. MacPherson. 2002. Migrating intestinal dendritic cells transport PrP(Sc) from the gut. J. Gen. Virol. 83:267.[Abstract/Free Full Text]

This article has been cited by other articles:

				L. L. P. Hosszu, C. R. Trevitt, S. Jones, M. Batchelor, D. J. Scott, G. S. Jackson, J. Collinge, J. P. Waltho, and A. R. Clarke Conformational Properties of {beta}-PrP J. Biol. Chem., August 14, 2009; 284(33): 21981 - 21990. [Abstract] [Full Text] [PDF]

				S. V. Antonyuk, C. R. Trevitt, R. W. Strange, G. S. Jackson, D. Sangar, M. Batchelor, S. Cooper, C. Fraser, S. Jones, T. Georgiou, et al. Crystal structure of human prion protein bound to a therapeutic antibody PNAS, February 24, 2009; 106(8): 2554 - 2558. [Abstract] [Full Text] [PDF]

				A. Sacquin, A. S. Bergot, P. Aucouturier, and M. Bruley-Rosset Contribution of Antibody and T Cell-Specific Responses to the Progression of 139A-Scrapie in C57BL/6 Mice Immunized with Prion Protein Peptides J. Immunol., July 1, 2008; 181(1): 768 - 775. [Abstract] [Full Text] [PDF]

				G. Kaiser-Schulz, A. Heit, L. Quintanilla-Martinez, F. Hammerschmidt, S. Hess, L. Jennen, H. Rezaei, H. Wagner, and H. M. Schatzl Polylactide-Coglycolide Microspheres CoEncapsulating Recombinant Tandem Prion Protein with CpG-Oligonucleotide Break Self-Tolerance to Prion Protein in Wild-Type Mice and Induce CD4 and CD8 T Cell Responses J. Immunol., September 1, 2007; 179(5): 2797 - 2807. [Abstract] [Full Text] [PDF]

				D. S. Spinner, R. B. Kascsak, G. LaFauci, H. C. Meeker, X. Ye, M. J. Flory, J. I. Kim, G. B. Schuller-Levis, W. R. Levis, T. Wisniewski, et al. CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils J. Leukoc. Biol., June 1, 2007; 81(6): 1374 - 1385. [Abstract] [Full Text] [PDF]

				C. R Trevitt and J. Collinge A systematic review of prion therapeutics in experimental models Brain, September 1, 2006; 129(9): 2241 - 2265. [Abstract] [Full Text] [PDF]

				P. A. Lewis, M. H. Tattum, S. Jones, D. Bhelt, M. Batchelor, A. R. Clarke, J. Collinge, and G. S. Jackson Codon 129 polymorphism of the human prion protein influences the kinetics of amyloid formation. J. Gen. Virol., August 1, 2006; 87(Pt 8): 2443 - 2449. [Abstract] [Full Text] [PDF]

				J. D. F. Wadsworth, S. Joiner, J. M. Linehan, S. Cooper, C. Powell, G. Mallinson, J. Buckell, I. Gowland, E. A. Asante, H. Budka, et al. Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein Brain, June 1, 2006; 129(6): 1557 - 1569. [Abstract] [Full Text] [PDF]

				A. Khalili-Shirazi, L. Summers, J. Linehan, G. Mallinson, D. Anstee, S. Hawke, G. S. Jackson, and J. Collinge PrP glycoforms are associated in a strain-specific ratio in native PrPSc J. Gen. Virol., September 1, 2005; 86(9): 2635 - 2644. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khalili-Shirazi, A. Articles by Collinge, J. Search for Related Content PubMed PubMed Citation Articles by Khalili-Shirazi, A. Articles by Collinge, J. Pubmed/NCBI databases Substance via MeSH